Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Tetsuya Wakabayashi"'
Autor:
Yuu Okura, Yuri Ikawa-Teranishi, Akihiko Mizoroki, Noriyuki Takahashi, Takashi Tsushima, Machiko Irie, Zulkarnain Harfuddin, Momoko Miura-Okuda, Shunsuke Ito, Genki Nakamura, Hiroaki Takesue, Yui Ozono, Masamichi Nishihara, Kenta Yamada, Siok Wan Gan, Akira Hayasaka, Shinya Ishii, Tetsuya Wakabayashi, Masaru Muraoka, Nishiki Nagaya, Hiroshi Hino, Takayuki Nemoto, Taichi Kuramochi, Takuya Torizawa, Hideaki Shimada, Takehisa Kitazawa, Makoto Okazaki, Junichi Nezu, Ludvig M. Sollid, Tomoyuki Igawa
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract In human celiac disease (CeD) HLA-DQ2.5 presents gluten peptides to antigen-specific CD4+ T cells, thereby instigating immune activation and enteropathy. Targeting HLA-DQ2.5 with neutralizing antibody for treating CeD may be plausible, yet u
Externí odkaz:
https://doaj.org/article/bd4902c569894da788e57ae0094f2b7a
Autor:
Shunsuke Ito, Tatsuya Ikuno, Masayuki Mishima, Mariko Yano, Toshiko Hara, Taichi Kuramochi, Zenjiro Sampei, Tetsuya Wakabayashi, Mitsuyasu Tabo, Shuichi Chiba, Chiyomi Kubo
Publikováno v:
Journal of Immunotoxicology, Vol 16, Iss 1, Pp 125-132 (2019)
Monoclonal antibody (mAb) drugs offer a number of valuable treatments. Many newly developed mAb drugs include artificial modification of amino acid sequences from human origin, which may cause higher immunogenicity to induce anti-drug antibodies (ADA
Externí odkaz:
https://doaj.org/article/865b1a01b0cb44aba41b7a5a0489c967
Autor:
Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Tatsuhiko Tachibana, Yuki Iwayanagi, Futa Mimoto, Yoshinobu Higuchi, Shinya Ishii, Shigero Tamba, Naoka Hironiwa, Kozue Nagano, Tetsuya Wakabayashi, Hiroyuki Tsunoda, Kunihiro Hattori
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e63236 (2013)
Monoclonal antibodies are widely used to target disease-related antigens. However, because conventional antibody binds to the antigen but cannot eliminate the antigen from plasma, and rather increases the plasma antigen concentration by reducing the
Externí odkaz:
https://doaj.org/article/5e72165db2b0430682a83824010d9f36
Autor:
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, Takehisa Kitazawa, Kazutaka Yoshihashi, Aya Harada, Miho Funaki, Kenta Haraya, Tatsuhiko Tachibana, Sachiyo Suzuki, Keiko Esaki, Yoshiaki Nabuchi, Kunihiro Hattori
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e57479 (2013)
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors). To overcome these drawbacks, we screened asymmetric bisp
Externí odkaz:
https://doaj.org/article/9f57fabaafda4b53b4d59a5865060934
Autor:
Tomoyuki Igawa, Takehisa Kitazawa, Yoshiki Kawabe, Kou-ichi Jishage, Mika Endo, Yoshito Nakanishi, Otoya Ueda, Atsuhiko Kato, Noriaki Sawada, Yasushi Tomii, Fumihisa Isomura, Masaki Kamimura, Tetsuya Wakabayashi, Ami Ito, Haruka Kuroi, Junko Shinozuka, Yuki Noguchi, Motohiko Sato, Yasuko Satoh, Nasa Savory, Sotaro Naoi, Koki Hamada, Ayano Hirako, Sayuri Horikawa, Akihisa Sakamoto, Shun-ichiro Komatsu, Shojiro Kadono, Tomochika Matsushita, Tetsushi Sakiyama, Kenji Adachi, Natsuki Ono, Tatsuhiko Tachibana, Hirofumi Mikami, Shun Shimizu, Yuki Ohte, Naoko A. Wada, Taro Miyazaki, Shoichi Metsugi, Meiri Shida-Kawazoe, Kenji Taniguchi, Naoka Hironiwa, Masaki Honda, Ryo Uchikawa, Takayuki Nemoto, Yuji Hori, Yoshinori Narita, Mika Kamata-Sakurai
Supplementary figures, tables, material and methods, and references
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef075e9b136326aba4e8a3303859f52
https://doi.org/10.1158/2159-8290.22535753.v1
https://doi.org/10.1158/2159-8290.22535753.v1
Autor:
Yuri Teranishi-Ikawa, Tetsuhiro Soeda, Hikaru Koga, Kazuki Yamaguchi, Kazuki Kato, Keiko Esaki, Kentaro Asanuma, Miho Funaki, Mina Ichiki, Yuri Ikuta, Shunsuke Ito, Eri Joyashiki, Shun-Ichiro Komatsu, Atsushi Muto, Kei Nishimura, Momoko Okuda, Hisakazu Sanada, Motohiko Sato, Norihito Shibahara, Tetsuya Wakabayashi, Koji Yamaguchi, Akiko Matsusaki, Zenjiro Sampei, Hirotake Shiraiwa, Hiroko Konishi, Yoshiki Kawabe, Kunihiro Hattori, Takehisa Kitazawa, Tomoyuki Igawa
Emicizumab, a factor (F)VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment for people with hemophilia A (PwHA). Although emicizumab is very potent, long-term outcomes from the clinical studies sugg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65e05c434bee4d4affb01dcc8f26f39e
https://doi.org/10.1101/2022.12.19.520692
https://doi.org/10.1101/2022.12.19.520692
Autor:
Tatsuhiko Tachibana, Nasa Savory, Otoya Ueda, Sayuri Horikawa, Tetsushi Sakiyama, Tomochika Matsushita, Yuji Hori, Kou-ichi Jishage, Haruka Kuroi, Motohiko Sato, Tetsuya Wakabayashi, Junko Shinozuka, Naoka Hironiwa, Meiri Shida-Kawazoe, Kenji Adachi, Ryo Uchikawa, Taro Miyazaki, Koki Hamada, Masaki Honda, Fumihisa Isomura, Mika Endo, Mika Kamata-Sakurai, Yoshito Nakanishi, Yuki Noguchi, Natsuki Ono, Yasuko Satoh, Yuki Ohte, Tomoyuki Igawa, Ayano Hirako, Hirofumi Mikami, Naoko A. Wada, Noriaki Sawada, Takehisa Kitazawa, Yasushi Tomii, Shun-ichiro Komatsu, Takayuki Nemoto, Yoshinori Narita, Kenji Taniguchi, Shun Shimizu, Naoi Sotaro, Akihisa Sakamoto, Shojiro Kadono, Yoshiki Kawabe, Atsuhiko Kato, Kamimura Masaki, Shoichi Metsugi, Ami Ito
Publikováno v:
Cancer Discovery. 11:158-175
Agonistic antibodies targeting CD137 have been clinically unsuccessful due to systemic toxicity. Because conferring tumor selectivity through tumor-associated antigen limits its clinical use to cancers that highly express such antigens, we exploited
Autor:
Ching Tim Jang, Jun-ichi Nezu, Yuichiro Shimizu, Chia Wei Shan, Tomoyuki Igawa, Chen Chen, Chong Chor Kun, Ishin Soehano, Masaru Muraoka, Tetsuya Wakabayashi, Feng Shu
Publikováno v:
mAbs. 11:632-638
The complex molecular formats of recent therapeutic antibodies, including bispecific antibodies, antibody fragments, and other fusion proteins, makes the task of purifying the desired molecules in a limited number of purification steps more and more
Autor:
Chiyomi Kubo, Taichi Kuramochi, Shuichi Chiba, Masayuki Mishima, Tetsuya Wakabayashi, Mitsuyasu Tabo, Toshiko Hara, Shunsuke Ito, Tatsuya Ikuno, Zenjiro Sampei, Mariko Yano
Publikováno v:
Journal of Immunotoxicology, Vol 16, Iss 1, Pp 125-132 (2019)
Monoclonal antibody (mAb) drugs offer a number of valuable treatments. Many newly developed mAb drugs include artificial modification of amino acid sequences from human origin, which may cause higher immunogenicity to induce anti-drug antibodies (ADA
Autor:
Hiroo Watanabe, Hiroyuki Tsunoda, Kenta Haraya, Yoshinao Ruike, Tetsuya Wakabayashi, Tatsuhiko Tachibana, Norihito Shibahara, Mitsuko Shibuya, Naoaki Murao, Akihisa Sakamoto, Zenjiro Sampei
Publikováno v:
The AAPS Journal. 23